环丝氨酸 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "环丝氨酸" in Chinese language version.

refsWebsite

Global rank Chinese rank

17doi.org

2^nd place

23^rd place

13nih.gov

4^th place

5^th place

7web.archive.org

1^st place

2semanticscholar.org

11^th place

332^nd place

2archive.org

6^th place

4^th place

2nytimes.com

7^th place

31^st place

1worldcat.org

5^th place

12^th place

1drugs.com

399^th place

208^th place

1books.google.com

3^rd place

8^th place

1handle.net

102^nd place

492^nd place

1scientificamerican.com

896^th place

1,333^rd place

1psychiatrist.com

low place

archive.org

Lambert MP, Neuhaus FC. Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W. Journal of Bacteriology. June 1972, 110 (3): 978–87. PMC 247518 . PMID 4555420. doi:10.1128/JB.110.3.978-987.1972.
Goff DC. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophrenia Bulletin. September 2012, 38 (5): 936–41. PMC 3446239 . PMID 22368237. doi:10.1093/schbul/sbs012.

books.google.com

Gottlieb D, Shaw PD. Mechanism of Action. Springer Science & Business Media. 2012: 41. ISBN 9783642460517. （原始内容存档于2016-12-20）（英语）.

doi.org

Polc, P.; Pieri, L.; Bonetti, E.P.; Scherschlicht, R.; Moehler, H.; Kettler, R.; Burkard, W.; Haefely, W. l-Cycloserine: Behavioural and biochemical effects after single and repeated administration to mice, rats and cats. Neuropharmacology (Elsevier BV). 1986, 25 (4): 411–418. ISSN 0028-3908. PMID 3012401. S2CID 462885. doi:10.1016/0028-3908(86)90236-4.
Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W. Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology. August 2004, 29 (8): 1573–8. PMID 15199378. doi:10.1038/sj.npp.1300517 .
Ori R, Amos T, Bergman H, Soares-Weiser K, Ipser JC, Stein DJ. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. The Cochrane Database of Systematic Reviews. May 2015, 5 (5): CD007803. PMID 25957940. doi:10.1002/14651858.CD007803.pub2.
Schade S, Paulus W. D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review. The International Journal of Neuropsychopharmacology. April 2016, 19 (4): pyv102. PMC 4851259 . PMID 26364274. doi:10.1093/ijnp/pyv102.
Myers KM, Carlezon WA. D-cycloserine effects on extinction of conditioned responses to drug-related cues. Biological Psychiatry. June 2012, 71 (11): 947–55. PMC 4001849 . PMID 22579305. doi:10.1016/j.biopsych.2012.02.030.
Lambert MP, Neuhaus FC. Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W. Journal of Bacteriology. June 1972, 110 (3): 978–87. PMC 247518 . PMID 4555420. doi:10.1128/JB.110.3.978-987.1972.
Prosser GA, de Carvalho LP. Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine. The FEBS Journal. February 2013, 280 (4): 1150–66. PMID 23286234. S2CID 22305408. doi:10.1111/febs.12108 .
Kaushal G, Ramirez R, Alambo D, Taupradist W, Choksi K, Sirbu C. Initial characterization of D-cycloserine for future formulation development for anxiety disorders. Drug Discoveries & Therapeutics. October 2011, 5 (5): 253–60. PMID 22466372. doi:10.5582/ddt.2011.v5.5.253 .
Silverman R. An Aromatization Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase for the Antibiotic l-Cycloserine. Journal of the American Chemical Society. 1998, 120 (10): 2256–2267. doi:10.1021/ja972907b.
Kuehl Jr FA, Wolf FJ, Trenner NR, Peck RL, Buhs RP, Howe E, et al. D-4-Amino-3-isoxazolidinone, a new antibiotic. Journal of the American Chemical Society. 1955, 77 (8): 2344–5. doi:10.1021/ja01613a105.
Hidy PH, Hodge EB, Young VV, Harned RL, Brewer GA, Phillips WF, et al. Synthesis of D-4-amino-3-isoxazolidinone. Journal of the American Chemical Society. 1955, 77 (8): 2346–7. doi:10.1021/ja01613a107.
Hidy PH, Hodge EB, Young VV, Harned RL, Brewer GA, Phillips WF, et al. Structure and reactions of cycloserine. Journal of the American Chemical Society. 1955, 77 (8): 2345–6. doi:10.1021/ja01613a106.
Bowers ME, Ressler KJ. An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials. Biological Psychiatry. September 2015, 78 (5): E15–27. PMC 4527085 . PMID 26238379. doi:10.1016/j.biopsych.2015.06.008.
Hofmann SG, Wu QJ, Boettcher H. D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders. Biology of Mood & Anxiety Disorders. May 2013, 3 (1): 11. PMC 3686620 . PMID 23768232. doi:10.1186/2045-5380-3-11 .
Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacology & Therapeutics. May 2015, 149: 150–90. PMC 4380664 . PMID 25550231. doi:10.1016/j.pharmthera.2014.12.004.
Goff DC. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophrenia Bulletin. September 2012, 38 (5): 936–41. PMC 3446239 . PMID 22368237. doi:10.1093/schbul/sbs012.
Kantrowitz J, Halberstam B, Gangwisch J. Single-Dose Ketamine Followed by Daily d-Cycloserine in Treatment-Resistant Bipolar Depression. The Journal of Clinical Psychiatry. June 2015 [2022-11-12]. doi:10.4088/JCP.14l09527. （原始内容存档于2022-11-12）.

drugs.com

Cycloserine. The American Society of Health-System Pharmacists. [8 December 2016]. （原始内容存档于20 December 2016）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

nih.gov

ncbi.nlm.nih.gov

Polc, P.; Pieri, L.; Bonetti, E.P.; Scherschlicht, R.; Moehler, H.; Kettler, R.; Burkard, W.; Haefely, W. l-Cycloserine: Behavioural and biochemical effects after single and repeated administration to mice, rats and cats. Neuropharmacology (Elsevier BV). 1986, 25 (4): 411–418. ISSN 0028-3908. PMID 3012401. S2CID 462885. doi:10.1016/0028-3908(86)90236-4.
Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W. Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology. August 2004, 29 (8): 1573–8. PMID 15199378. doi:10.1038/sj.npp.1300517 .
Ori R, Amos T, Bergman H, Soares-Weiser K, Ipser JC, Stein DJ. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. The Cochrane Database of Systematic Reviews. May 2015, 5 (5): CD007803. PMID 25957940. doi:10.1002/14651858.CD007803.pub2.
Schade S, Paulus W. D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review. The International Journal of Neuropsychopharmacology. April 2016, 19 (4): pyv102. PMC 4851259 . PMID 26364274. doi:10.1093/ijnp/pyv102.
Myers KM, Carlezon WA. D-cycloserine effects on extinction of conditioned responses to drug-related cues. Biological Psychiatry. June 2012, 71 (11): 947–55. PMC 4001849 . PMID 22579305. doi:10.1016/j.biopsych.2012.02.030.
Lambert MP, Neuhaus FC. Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W. Journal of Bacteriology. June 1972, 110 (3): 978–87. PMC 247518 . PMID 4555420. doi:10.1128/JB.110.3.978-987.1972.
Prosser GA, de Carvalho LP. Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine. The FEBS Journal. February 2013, 280 (4): 1150–66. PMID 23286234. S2CID 22305408. doi:10.1111/febs.12108 .
Kaushal G, Ramirez R, Alambo D, Taupradist W, Choksi K, Sirbu C. Initial characterization of D-cycloserine for future formulation development for anxiety disorders. Drug Discoveries & Therapeutics. October 2011, 5 (5): 253–60. PMID 22466372. doi:10.5582/ddt.2011.v5.5.253 .
Bowers ME, Ressler KJ. An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials. Biological Psychiatry. September 2015, 78 (5): E15–27. PMC 4527085 . PMID 26238379. doi:10.1016/j.biopsych.2015.06.008.
Hofmann SG, Wu QJ, Boettcher H. D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders. Biology of Mood & Anxiety Disorders. May 2013, 3 (1): 11. PMC 3686620 . PMID 23768232. doi:10.1186/2045-5380-3-11 .
Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacology & Therapeutics. May 2015, 149: 150–90. PMC 4380664 . PMID 25550231. doi:10.1016/j.pharmthera.2014.12.004.
Goff DC. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophrenia Bulletin. September 2012, 38 (5): 936–41. PMC 3446239 . PMID 22368237. doi:10.1093/schbul/sbs012.

toxnet.nlm.nih.gov

CYCLOSERINE: Human Health Effects. National Institutes of Health. （原始内容存档于2014-04-16）.

nytimes.com

Pollack A. Drug Goes From $13.50 a Tablet to $750, Overnight. 20 September 2015 [21 September 2015]. （原始内容存档于25 September 2015）.
Pollack A. Big Price Increase for Tuberculosis Drug Is Rescinded. NYT. 21 September 2015 [24 September 2015]. （原始内容存档于26 September 2015）.

psychiatrist.com

Kantrowitz J, Halberstam B, Gangwisch J. Single-Dose Ketamine Followed by Daily d-Cycloserine in Treatment-Resistant Bipolar Depression. The Journal of Clinical Psychiatry. June 2015 [2022-11-12]. doi:10.4088/JCP.14l09527. （原始内容存档于2022-11-12）.

scientificamerican.com

Learning and Brain Activity Are Boosted by a Dose of a Small-Molecule Compound. Scientific American. （原始内容存档于2015-12-23）.

semanticscholar.org

api.semanticscholar.org

Polc, P.; Pieri, L.; Bonetti, E.P.; Scherschlicht, R.; Moehler, H.; Kettler, R.; Burkard, W.; Haefely, W. l-Cycloserine: Behavioural and biochemical effects after single and repeated administration to mice, rats and cats. Neuropharmacology (Elsevier BV). 1986, 25 (4): 411–418. ISSN 0028-3908. PMID 3012401. S2CID 462885. doi:10.1016/0028-3908(86)90236-4.
Prosser GA, de Carvalho LP. Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine. The FEBS Journal. February 2013, 280 (4): 1150–66. PMID 23286234. S2CID 22305408. doi:10.1111/febs.12108 .

web.archive.org

Cycloserine. The American Society of Health-System Pharmacists. [8 December 2016]. （原始内容存档于20 December 2016）.
Gottlieb D, Shaw PD. Mechanism of Action. Springer Science & Business Media. 2012: 41. ISBN 9783642460517. （原始内容存档于2016-12-20）（英语）.
CYCLOSERINE: Human Health Effects. National Institutes of Health. （原始内容存档于2014-04-16）.
Pollack A. Drug Goes From $13.50 a Tablet to $750, Overnight. 20 September 2015 [21 September 2015]. （原始内容存档于25 September 2015）.
Pollack A. Big Price Increase for Tuberculosis Drug Is Rescinded. NYT. 21 September 2015 [24 September 2015]. （原始内容存档于26 September 2015）.
Learning and Brain Activity Are Boosted by a Dose of a Small-Molecule Compound. Scientific American. （原始内容存档于2015-12-23）.
Kantrowitz J, Halberstam B, Gangwisch J. Single-Dose Ketamine Followed by Daily d-Cycloserine in Treatment-Resistant Bipolar Depression. The Journal of Clinical Psychiatry. June 2015 [2022-11-12]. doi:10.4088/JCP.14l09527. （原始内容存档于2022-11-12）.

worldcat.org

Polc, P.; Pieri, L.; Bonetti, E.P.; Scherschlicht, R.; Moehler, H.; Kettler, R.; Burkard, W.; Haefely, W. l-Cycloserine: Behavioural and biochemical effects after single and repeated administration to mice, rats and cats. Neuropharmacology (Elsevier BV). 1986, 25 (4): 411–418. ISSN 0028-3908. PMID 3012401. S2CID 462885. doi:10.1016/0028-3908(86)90236-4.